Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a clinical-stage biotechnology company focused on developing innovative therapies for cancer and other serious diseases, has announced that its CEO and Chairman, Dr. Vuong Trieu, will present at the OTCQB Virtual Investor Conference on August 6, 2026, at 2:30 p.m. ET. The presentation will include a live question-and-answer session, offering investors direct insight into the company’s recent advancements.
The company plans to highlight several key milestones, including the advancement of its Phase 1b intravenous Everolimus (Sapu003) trial to the next dose cohort. This move signals progress in the clinical development of a potential treatment that may offer a new delivery method for a known drug. Everolimus is currently used in various cancer types, and an intravenous formulation could improve its efficacy and patient convenience.
Additionally, Oncotelic is expanding its European clinical sites, which may accelerate patient enrollment and diversify the trial data. The company has also validated its proprietary Deciparticle™ platform through peer-reviewed publications, lending scientific credibility to its drug delivery technology. The Deciparticle platform is designed to enhance the delivery of therapeutics, potentially increasing their effectiveness and reducing side effects.
Another focus will be on the company’s scalable cGMP manufacturing capabilities, which are crucial for transitioning from clinical trials to commercial production. This capability could be a significant asset as the company progresses its pipeline.
Furthermore, Oncotelic continues to develop its AI-driven drug discovery, robotics, and nanomedicine platforms. These technologies aim to accelerate the identification of new drug candidates and optimize their design, potentially leading to more effective and personalized treatments. The integration of AI in drug discovery is a growing trend in the biotech industry, and Oncotelic’s efforts may position it at the forefront of this innovation.
The presentation at the OTCQB Virtual Investor Conference provides a platform for the company to communicate its progress to investors and the broader financial community. It underscores the company’s commitment to transparency and engagement with its shareholders. The live Q&A session will allow investors to directly ask questions, fostering a deeper understanding of the company’s strategy and outlook.
For those interested in more detailed information, the full press release is available at https://nnw.fm/fGHUt. Additionally, the latest news and updates regarding OTLC can be found in the company’s newsroom at https://nnw.fm/OTLC.
This announcement is significant as it highlights the company’s ongoing efforts to advance its clinical programs and leverage cutting-edge technologies. The progress in the Everolimus trial and the validation of the Deciparticle platform could have implications for the future of cancer therapy. Moreover, the expansion into European sites and the focus on scalable manufacturing indicate a strategic approach to bringing these therapies to market.
Investors and industry observers will be watching closely to see how these developments unfold. The presentation at the conference could provide valuable insights into the company’s near-term milestones and long-term vision.
